Revenue Growth - Total revenues for the three months ended October 31, 2021, increased by 109% to $5,514,000 compared to $2,641,000 for the same period in 2020[137]. - Software as a Service (SaaS) revenue for the three months ended October 31, 2021, increased by 214% to $2,825,000 from $900,000 in the prior year[137]. - Professional services revenue for the three months ended October 31, 2021, increased by 486% to $944,000 compared to $161,000 in the same period last year[137]. - The company recorded $814,000 in professional services revenue from Avelead since its acquisition, contributing to the overall increase in professional services revenue[139]. Expenses - Selling, general, and administrative expenses for the three months ended October 31, 2021, increased by 51% to $3,439,000 from $2,283,000 in the prior year[147]. - Cost of sales for the three months ended October 31, 2021, increased by 77% to $2,623,000 compared to $1,479,000 in the same period last year[142]. - Research and development expenses for the three months ended October 31, 2021 were $1,339,000, a 78% increase from $753,000 in the prior year[149]. - Total research and development costs for the nine months ended October 31, 2021 were $4,328,000, a 24% increase from $3,491,000 in the prior year[150]. - Sales and marketing expenses increased by approximately $267,000 for the three and nine months ended October 31, 2021, primarily due to the Avelead acquisition and expansion of sales personnel[148]. - Non-routine costs for the three months ended October 31, 2021 were $1,933,000, representing a 100% increase compared to the prior year[151]. Financial Performance - For the three months ended October 31, 2021, the company reported a loss from continuing operations of $4,379,000 compared to a loss of $1,069,000 for the same period in 2020[166]. - The company reported a net loss from continuing operations of $(6,913,000) for the nine months ended October 31, 2021, compared to $(3,209,000) for the same period in 2020[178]. - Adjusted EBITDA for the nine months ended October 31, 2021 was $(1,737,000), an improvement from $(1,741,000) in the same period of 2020, with an adjusted EBITDA margin of (15%) compared to (21%) in 2020[166]. - The company had a diluted loss per share of $(0.10) for the three months ended October 31, 2021, compared to $(0.04) for the same period in 2020[166]. Cash Flow and Financing - The company had cash and cash equivalents of approximately $10,409,000 as of October 31, 2021, up from $2,409,000 at January 31, 2021[171]. - The company raised approximately $16.1 million from a public offering of 10,062,500 shares of common stock at $1.60 per share, which closed on March 2, 2021[171]. - The company invested $12,354,000 in Avelead during the nine months ended October 31, 2021, with net cash used in investing activities totaling $(12,620,000)[179]. - Net cash used in operating activities for the nine months ended October 31, 2021 was $(4,022,000), compared to $(3,683,000) for the same period in 2020[178]. - The company received a new term loan facility with a maximum principal amount of $10,000,000, which bears interest at a rate equal to the Prime Rate plus 1.5%[172]. - The company recorded a forgiveness of a PPP loan and accrued interest amounting to $2,327,000 for the nine months ended October 31, 2021[155]. Strategic Acquisitions - The acquisition of Avelead on August 16, 2021, is expected to enhance the company's revenue integrity solutions for healthcare providers[135]. - The company experienced a shift from perpetual software licenses to Software as a Service (SaaS) offerings, impacting revenue recognition[138]. - The company expects total research and development expenses to continue increasing due to ongoing projects related to Avelead and eValuator[150]. Other Financial Metrics - Total other income (expense) for the three months ended October 31, 2021 was $(555,000), a significant decrease from $2,000 in the prior year, reflecting a 27,850% change[154]. - Interest expense for the nine months ended October 31, 2021 was $(107,000), a 174% increase from $(39,000) in the prior year[154]. - The company has a substantial amount of net operating losses for federal and state income tax purposes, with an income tax expense of $9,000 for the nine months ended October 31, 2021[156]. - The company recorded a loss on exit from a membership agreement of $105,000 in the nine months ended October 31, 2020, which was not present in the current year[152]. - The company anticipates lower SaaS revenues in the fourth quarter due to slower contracting processes attributed to COVID-19[141]. - The company was in compliance with the covenants of the Second Amended Loan and Security Agreement for the period ended October 31, 2021[173].

Company Participants Jacob Goldberger - Director of Investor Relations Tee Green - President & Chief Executive Officer Randy Salisbury - Chief Sales & Marketing Officer Tom Gibson - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Brooks O'Neil - Lake Street Capital Markets Disclaimer*: This transcript is designed to be used alongside the freely available audio recording on this page. Timestamps within the transcript are designed to help you navigate the audio sh ...

EEEOOOAA eValuator™ Inpatien shboar Final act Accuracy Workflow Service Provider -12/31/18 国 | Your Service Provider our Client ::::::: Streamline $ 370,982 . Health® ������ ■ ■ ● ● ● ● ● ● ● ● ● ● ● ● . . . ■ ■ ■ ■ ■ ■ Third Quarter 2021 Earnings Presentation Apr > ■■●●●●●●●●●■■ Nasdaq: STRM EHEAAAA ......... ........ HEECOOAAA Disclosure Statement SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Liti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to____________ Commission File Number: 000-28132 STREAMLINE HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) (State or oth ...

Financial Data and Key Metrics Changes - Total revenue for Q2 2021 was $2.9 million, consistent with Q2 2020, while SaaS revenue grew by 59% year-over-year [10][22] - Recurring revenue accounted for 84% of total revenue in Q2 2021, up from 71% in Q2 2020 [10] - Adjusted EBITDA for Q2 2021 was a loss of $800,000, compared to a loss of $400,000 in Q2 2020 [10][25] - Cash on hand as of July 31, 2021, was $15.8 million, with no bank debt [10][26] Business Line Data and Key Metrics Changes - SaaS revenue increased by $0.5 million, approximately 59% compared to the same quarter a year ago [22] - Avelead's SaaS ARR run rate was $5.7 million as of June 30, 2021, with total revenue for the trailing 12 months at $10.2 million [12] Market Data and Key Metrics Changes - The company experienced decision-making delays in healthcare providers due to the Delta variant, impacting elective procedures and revenue generation [19][40] - The sales pipeline for eValuator contracts remains strong, with approximately $1.5 million in contracts sold in Q2 2021 [19] Company Strategy and Development Direction - The acquisition of Avelead is seen as a major milestone, expected to nearly double consolidated revenue and enhance the product portfolio [12][28] - The company aims to achieve a gross margin of 80% for SaaS revenue by fiscal 2023 [26][27] Management's Comments on Operating Environment and Future Outlook - Management remains optimistic about growth despite the challenges posed by the pandemic, focusing on technologies that improve financial performance for healthcare providers [28][29] - The company is confident in its ability to generate cash flow by Q2 or Q3 2022 following the acquisition of Avelead [27] Other Important Information - The company has made significant strides in cleaning up its capital structure, including eliminating preferred stock and raising $16 million in March 2021 [11] - The leadership team is focused on expanding sales and marketing efforts, with new hires to support growth initiatives [20][21] Q&A Session Summary Question: Feedback from Avelead customers and cross-selling opportunities - Management confirmed positive feedback from Avelead customers and identified opportunities for cross-selling between eValuator and Avelead solutions [33][34] Question: Potential to add eValuator to Cerner distribution agreement - Management expressed interest in introducing eValuator to Cerner teams at the appropriate time, highlighting the complementary nature of their solutions [36] Question: Triggers for customers to finalize contracts - Management noted that the backlog in legal departments and the urgency of revenue loss are key factors that will drive contract signings [38][41] Question: Avelead's market position before acquisition - Avelead was exploring growth opportunities and had engaged in discussions with Streamline prior to the acquisition [44][46]

eValuator Mnpatien. shboar Fina /12/21/18 日 Your Secritics Privider 1,855,250 $ 1,484,268 Accuracy Workflow $ 370,982 Streamline Health® Second Quarter 2021 Earnings Presentation Nasdaq: STRM Cur Disclosure Statement SAFE HARBOR STATEMENT: FORWARD-LOOKING DISCLOSURE This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, based on current management expectations. Because forward-looking statements relate to the future, they are ...

Financial Performance - SaaS revenue grew by 32% from $0.9 million in 1Q20 to $1.2 million in 1Q21[6] - The company had $16.7 million in cash and cash equivalents as of April 30, 2021[6] - Net income improved significantly from a loss of $2.1 million to a profit of $3.7 million[9] - Operating expenses decreased from $5.4 million to $4.4 million[9] - Total new bookings during 1Q21 were $2.6 million[6] Balance Sheet - Cash and cash equivalents increased from $2.4 million to $16.7 million between January 31, 2021 and April 30, 2021[11] - Total current assets increased from $7.3 million to $21.6 million between January 31, 2021 and April 30, 2021[11] Sales and Future Outlook - The company aims to maintain a $2-$3 million quarterly bookings goal[8] - The company is focused on persistent, sequential revenue growth[13] - The company anticipates cash from operations breakeven during 2Q or 3Q 2022[13]

Streamline Health Solutions, Inc. (NASDAQ:STRM) Q1 2021 Earnings Conference Call June 9, 2021 9:00 AM ET Company Participants Jacob Goldberger - IR Tee Green - President & CEO Tom Gibson - CFO Randy Salisbury - Chief Sales & Marketing Officer Conference Call Participants Matt Hewitt - Craig-Hallum Operator Hello, and welcome to the Streamline Health Solutions First Quarter 2021 Earnings Conference Call and Webcast. [Operator Instructions] As a reminder, this conference is being recorded. It's now my pleasur ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2021 OR [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________to____________ Commission File Number: 000-28132 STREAMLINE HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its charter) Delaware ...

Streamline Health Solutions, Inc. (NASDAQ:STRM) Q4 2020 Earnings Conference Call April 22, 2021 9:00 AM ET Company Representatives Tee Green - President, Chief Executive Officer, Chairman Tom Gibson - Chief Financial Officer Randy Salisbury - Senior Vice President, Chief Sales and Marketing Officer Conference Call Participants Matt Hewitt - Craig-Hallum Operator Hello! And welcome to the Streamline Health Solutions, Fourth Quarter and Fiscal Year 2020 Earnings Conference Call and Webcast. At this time all p ...